Risk of Unintentional Overdose with Non-Prescription Acetaminophen Products
- 1k Downloads
There is increasing concern over the risk of consumer unintentional misuse of non-prescription (a.k.a. ‘over-the-counter’) medications containing acetaminophen, which could lead to acute liver failure.
To determine the prevalence of potential misuse and overdose of over-the-counter medications containing acetaminophen, either alone or in combination.
Cross-sectional, structured interviews with literacy assessment.
One academic and one community-based general internal medicine practice in Chicago, IL, and one academic general internal medicine practice and a public hospital clinic in Atlanta, GA.
Five hundred adults seeking primary care, ages 18–80.
Demonstration of how and when patients would take over-the-counter medications containing acetaminophen, alone or in combination with one another, over a 24-hour period.
Overall, 23.8 % of participants demonstrated they would overdose on a single over-the-counter acetaminophen product by exceeding a dose of four grams in a 24-hour period; 5.2 % made serious errors by dosing out more than six grams. In addition, 45.6 % of adults demonstrated they would overdose by ‘double-dipping’ with two acetaminophen-containing products. In multivariable analyses, limited literacy (Relative Risk Ratio (RR) 1.65, 95 % Confidence Interval (CI) 1.03–2.66) and heavy acetaminophen use in the past six months (RR 1.70, 95 % CI 1.10–2.64) were independently associated with overdosing over-the-counter products.
Misunderstanding of the active ingredient and proper instructions for over-the-counter medications containing acetaminophen is common. The potential for errors and adverse events associated with unintentional misuse of these products is substantial, particularly among heavy users of acetaminophen and those with limited literacy.
KEY WORDSover-the-counter drugs medication health literacy understanding knowledge medication errors acetaminophen pain
This project was supported by an unrestricted grant from McNeil Consumer Healthcare (PI: Wolf). The funding for this study was under an Investigator-Initiated Research (IIR) mechanism through McNeil Consumer Healthcare, and the funder had no role in the study design, data collection, analysis, or interpretation of findings
Conflict of Interest
Drs. Wolf and Davis have previously provided research consultation services (health literacy, study design for comprehension testing for OTC product use) for McNeil Consumer Healthcare. Dr. Wolf and Stacy Bailey are Consultants to Abbott Labs. All other authors declare they do not have a conflict of interest.
- 2.Department of Health and Human Services. Over-the-counter human drugs; labeling requirements; final rule. Fed Regist. 1999;64:13254–13303.Google Scholar
- 7.Slone Epidemiology Center. Patterns of Medication Use in the United States 2006: A Report from the Slone Survey. 2006. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf. (Accessed April 6, 2012).
- 10.Manthripragada AD, Zhou EH, Budnitz DS, Lovegrove MC, Willy ME. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. Pharmacoepidemiol Drug Saf. 2011;8:19–826.Google Scholar
- 14.Summary Minutes of the Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee, June 29 and 30, 2009. 2009 Meeting Materials, Drug Safety and Risk Management Advisory Committee 2009. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm126014.htm. (Accessed April 6, 2012).
- 16.American Association for Public Opinion Research. Standard definitions: Final dispositions of case codes and outcome rates for surveys. 2011. http://www.aapor.org/For_Researchers/4362.htm. (Accessed 15 August, 2011).
- 20.Davis CS. Statistical methods for the analysis of repeated measurements. New York: Springer-Verlag; 2002.Google Scholar
- 27.Department of Health and Human Services. Organ-specific warnings; internal analgesic, antipyretic and antirheumatic drug products for over-the-counter human use; final monograph. Fed Regist. 2009;74:19385–19409.Google Scholar
- 28.McNeil Consumer Healthcare. New Initiative to Help Encourage Appropriate Use of Acetaminophen. 2011. http://www.tylenol.com/page2.jhtml?id=tylenol/news/newdosing.inc. (Accessed April 6, 2012)
- 29.National Coalition for Prescription Drug Programs. NCPDP Recommendations for Improved Prescription Container Labels for Medicines Containing Acetaminophen. Scottsdale, AZ; July 2011). http://www.fda.gov/downloads/Drugs/DrugSafety/UCM266631.pdf (Accessed April 6, 2012).
- 30.Federal Trade Commission (2010c), “Regulation of nonprescription drug products”, Federal Trade Commission. Available at: www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM148055.pdf (Accessed April 6, 1202).
- 31.U.S. Food and Drug Administration. Safe Use Initiative: Collaborating to Reduce Preventable Harm from Medications. Drug Safety and Availability, 2011. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM188961.pdf (Accessed April 16, 2011).
- 32.Centers for Disease Control and Prevention. The PROTECT Initiative: Advancing Children's Medication Safety. Medication Safety Program, 2011. http://www.cdc.gov/MedicationSafety/protect/protect_Initiative.html. (Accessed April 6, 2012).